COVID-19 Outbreak-Global Fabry Disease Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
- 109 Pages
- Region: Global
Fabry disease is a rare hereditary disease that affects many parts of the body. Fabry disease is one of a group of diseases called lysosomal storage diseases. Mutations in genes that cause Fabry disease interfere with the function of enzymes that process biomolecules called sphingolipids, causing them to accumulate in blood vessel walls and other organs. It is inherited by X link.
The Fabry Disease market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.
Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.
In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the Fabry Disease industry.
Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy.
The Fabry Disease market can be split based on product types, major applications, and important countries as follows:
Key players in the global Fabry Disease market covered in Chapter 12:
ISU Abxis Co Ltd.
Green Cross Pharma Pte Ltd.
Protalix Biotherapeutics Inc.
JCR Pharmaceuticals Co Ltd.
Moderna Therapeutics Inc.
Amicus Therapeutics Inc.
Idorsia Pharmaceuticals Ltd.
Greenovation Biotech GmbH
In Chapter 4 and 14.1, on the basis of types, the Fabry Disease market from 2015 to 2025 is primarily split into:
In Chapter 5 and 14.2, on the basis of applications, the Fabry Disease market from 2015 to 2025 covers:
Enzyme Replacement Therapy (ERT)
Substrate Reduction Therapy (SRT)
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 6, 7, 8, 9, 10, 11, 14:
North America (Covered in Chapter 7 and 14)
Europe (Covered in Chapter 8 and 14)
Asia-Pacific (Covered in Chapter 9 and 14)
Middle East and Africa (Covered in Chapter 10 and 14)
South America (Covered in Chapter 11 and 14)
Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025